The Cigna Group is a global health services company that operates through two primary segments: Evernorth Health Services, one of the largest pharmacy benefit managers and health services platforms in the world, and Cigna Healthcare, which provides medical insurance and related services. Following the sale of its individual Medicare Advantage business, Cigna has sharpened its focus on employer-sponsored health plans and pharmacy services.
At $289.48, Cigna is a large-cap healthcare name with a distinctive business mix. Evernorth processes billions of pharmaceutical claims annually and provides specialty pharmacy, behavioural health, and care management services. This segment generates steady, predictable revenue with attractive margins. The healthcare insurance segment covers tens of millions of lives through employer and government programmes.
Cigna is included in our Titan composite screening as a healthcare company that combines defensive characteristics with genuine growth potential. The pharmacy benefit management business is a toll-road on healthcare spending, generating revenue regardless of which drugs doctors prescribe or which conditions patients present with. That structural advantage is why Cigna deserves attention beyond the headline health insurance label.
Our multi-factor framework reads Cigna as being in a markup regime. The buying pressure is consistent and institutional in character, reflecting positioning by large funds that view Cigna as attractively valued relative to its peers and its own earnings growth trajectory.
The markup reflects several factors. The divestiture of the Medicare Advantage business simplified the company’s profile and removed a source of earnings volatility. Evernorth continues to grow as pharmacy costs rise and employers seek more sophisticated management of their drug spending. And Cigna’s aggressive share buyback programme has been reducing the share count, providing mechanical support to earnings per share growth.
Healthcare names in markup regimes tend to be among the more durable positions in a portfolio because the underlying demand drivers are non-cyclical. People need healthcare regardless of economic conditions. Employers need to provide health benefits to attract and retain workers. These are structural realities that underpin Cigna’s revenue base.
Track Cigna’s markup regime against other healthcare names at the Convergence Screener.
Cigna carries an 85.8 ethical score, which is strong for a health insurance company. The score reflects Cigna’s role in facilitating healthcare access and its corporate governance practices.
Health insurance companies face inherent ethical tension. On one hand, they enable millions of people to access medical care they could not otherwise afford. On the other, the industry faces criticism around coverage denials, cost-sharing burdens, and the complexity of the American healthcare system. Cigna’s score reflects a balance of these considerations.
Evernorth’s pharmacy services contribute positively to the ethical profile by helping manage drug costs and improve medication adherence, both of which produce better health outcomes. The company’s behavioural health programmes also address a critical need in mental healthcare access.
No material governance controversies have been flagged. Cigna maintains strong corporate governance standards as expected of a Fortune 15 company.
At $289.48, Cigna trades at a modest price-to-earnings multiple relative to the broader market, which is typical of managed care organisations. The discount reflects the regulatory risk that permanently hangs over the industry and the perceived commodity nature of health insurance.
The valuation does not fully credit the Evernorth platform, which arguably deserves a higher multiple than the insurance business given its more predictable revenue profile and growth characteristics. A sum-of-the-parts analysis suggests that the market may be undervaluing the pharmacy services business within the consolidated entity.
Medical cost trends: The medical loss ratio is the key profitability metric for the insurance segment. Rising medical costs that outpace premium increases compress margins. Monitor utilisation trends, particularly in specialty drugs and hospital services.
Evernorth client retention and growth: New contract wins and client retention rates signal the health of the pharmacy services platform. Client losses to competitors would be a material negative.
Regulatory environment: Healthcare regulation is a perennial risk. Pharmacy benefit manager reform, drug pricing legislation, and changes to employer healthcare mandates could all affect Cigna’s business model.
Share buyback pace: Cigna has been an aggressive repurchaser. Monitor the buyback programme’s pace and funding, as it has been a significant driver of earnings per share growth.
GLP-1 drug impact: The rise of GLP-1 medications for weight loss and diabetes is reshaping healthcare economics. Monitor how these high-cost drugs affect Cigna’s pharmacy costs and whether they ultimately reduce downstream medical expenses.
Full daily coverage is at Alpha Insights. Ticker page: CI Ticker Page.